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Abstract
Background: Many non-COVID-19 trials were disrupted in 2020 and either struggled to recruit participants or
stopped recruiting altogether. In December 2019, just before the pandemic, we were awarded a grant to conduct a
randomised controlled trial, the Should I Take Aspirin? (SITA) trial, in Victoria, the Australian state most heavily
affected by COVID-19 during 2020.
Main body: We originally modelled the SITA trial recruitment method on previous trials where participants were
approached and recruited in general practice waiting rooms. COVID-19 changed the way general practices worked,
with a significant increase in telehealth consultations and restrictions on in person waiting room attendance. This
prompted us to adapt our recruitment methods to this new environment to reduce potential risk to participants
and staff, whilst minimising any recruitment bias. We designed a novel teletrial model, which involved calling
participants prior to their general practitioner appointments to check their eligibility. We delivered the trial both
virtually and face-to-face with similar overall recruitment rates to our previous studies.
Conclusion: We developed an effective teletrial model which allowed us to complete recruitment at a high rate.
The teletrial model is now being used in our other primary care trials as we continue to face the impacts of the
COVID-19 pandemic.
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Background
To understand the breadth of research being conducted
globally, as of May 2020, ClinicalTrials.gov listed
351,526 ongoing randomised clinical trials, including
98,051 trials of behavioural interventions [1]. In response
to the COVID-19 pandemic about 80% of non-COVID-
19 trials were interrupted for several reasons including;
laboratories closing, a shutdown in communication and
because they were unable to be conducted whilst ensur-
ing recruitment safety and efficacy [2].
In December 2019, we were awarded a Victorian Can-
cer Agency grant to conduct the Should I Take Aspirin?
(SITA) trial, a randomised controlled trial of a decision
aid to support informed choices about taking aspirin to
reduce risk of bowel cancer and other chronic condi-
tions [3]. One month later in January 2020, the first case
of COVID-19 was detected in Australia, and by the end
of March, a national lockdown was in place [4]. The
Australian state of Victoria, where our study is being
conducted, has been most heavily impacted by COVID-
19 compared to the rest of the country. As of the 9 June
2021, Victoria, and mostly in Melbourne, recorded
20,650 out of 30,204 total cases of COVID-19 and 820
out of 910 deaths due to COVID-19 in Australia [5, 6].
To stop the spread of COVID-19 in Australia, lock-
downs have been put in place which included varying
degrees of self-isolation, limited travel, border closures
and only leaving home for daily exercise, buying essen-
tials, authorised work and medical care including getting
the COVID-19 test or vaccination [7]. In response to the
lockdown, there was a 30% decline in face-to-face gen-
eral practitioner (GP) appointments visits, which has
persisted, and a compensatory increase in telehealth
consultations [8, 9]. Consequently, commencing on 13
March 2020, new Medicare Benefits Schedule (MBS) tel-
ehealth item numbers were created to allow GP consul-
tations over the phone to be charged to the MBS,
Australia’s national healthcare scheme [10]. We had to
quickly adapt our trial to ensure successful recruitment
and thus completion of the trial, whilst accounting for
the shift from face to face consultations to consulting by
telehealth.
Recruiting patients from general practice clinics before
COVID-19
In our previous studies, participants were approached
and recruited in general practice waiting rooms [11–16].
One of our studies, the Colorectal cancer RISk Prediction
(CRISP) trial [17], which commenced in 2017, recruited
patients in general practice waiting rooms. This method
proved to be effective for patient level recruitment and
randomisation, thus we planned to model SITA’s re-
cruitment strategy after CRISP.
The recruitment method required two research assis-
tants (RAs) to be in the clinic at the same time; RA1
would approach patients in the waiting rooms whilst
RA2 would deliver the trial intervention. Each day in the
general practices, RA1 would coordinate with the prac-
tice manager and waiting room staff about potentially
eligible patients with GP appointments. RA1 would ap-
proach patients in the waiting rooms and invite them
into the trial. Only participants whose GPs were running
late by at least 15 min were approached.
RA1 would then take the patient to a private consult-
ation room with RA2. RA2 would check the participant’s
eligibility, gain informed consent, complete the baseline
questionnaire, randomise them and then deliver the
intervention, a risk assessment tool or control brochure
to the participant. RA1 would continue to approach pa-
tients in the waiting room whilst ensuring that if the GP
called the patient, the patient would be taken to the GP
appointment, regardless of whether the research consult-
ation was interrupted or not. From March 2017 to
March 2018, with two RA teams recruiting simultan-
eously, the study successfully recruited 734 participants,
the full sample size (65% of eligible participants) into the
trial, from 10 general practices.
Recruiting patients from general practice clinics after
COVID-19
COVID-19 meant fewer patients were attending prac-
tices and those who did were social distanced in waiting
rooms and often sat in their car until their appointment.
Our waiting room method of recruitment had to change.
We quickly pivoted and developed a novel teletrial
model for recruitment and delivery of the interventions
[3]. This involved calling patients who were scheduled
for a general practitioner appointment and checking
their eligibility over the phone. GPs gave us consent to
call patients from their practice, making it clear as part
of the telephone script that the research team were
working with the patient’s general practice as part of the
trial. We used the consenting GPs scheduled appoint-
ment list for the day and following day to identify people
who were 50–70 years old and applied the eligibility cri-
teria over the phone. If participants were eligible and in-
terested, they were scheduled for a either a Zoom [18]
or face-to-face consultation, depending on their appoint-
ment type with their GP, with RA2 10 to 15min prior to
their scheduled GP appointment, depending on the
clinic and length of GP appointment time, and whether
they were participating via Zoom. Whilst RAs worked in
the clinics, masks were worn at all times, the consulting
rooms were disinfected and social distancing measures
were followed.
Participants who participated via Zoom consented
electronically whilst face-to-face participants were given
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a new pen, to reduce transmission of COVID-19 and
consented on paper [3]. We developed trial recruitment
materials into a format suitable for sending via email
and/or through the post. We also developed videos that
presented the decision aid and control brochures. These
videos were presented via the Zoom teletrial consult-
ation through the screensharing function, and in the
face-to-face research consultations, which ensured that
the decision aids were delivered in a standardised man-
ner [3]. The video links can be found below.
Results
We have recently completed trial recruitment, and over
a 6-month period, we successfully randomised 264 par-
ticipants into the trial, our full sample size, with a re-
cruitment rate of 87% of eligible participants. 92.8% of
our participants were approached over the phone, and
20.8% were consented and received the interventions via
a Zoom consultation. The remainder elected to have
their GP consultation in person and so also had a face-
to-face trial consultation. The 8.2% of our participants
who were approached face-to-face were also phoned in
advance, but could not be contacted, so they were
approached in the general practice waiting room. The
teletrial recruitment rate was higher to that achieved in
our CRISP trial.
Conclusion
We have developed an effective teletrial model for the
SITA trial which has allowed us to continue during the
COVID-19 pandemic and provide more flexible partici-
pation options for participants, at a higher rate than the
CRISP trial. In so doing, we may have further minimised
potential recruitment biases inherent in our previous
methods. We are now applying the teletrial method to
other trials in general practice including beyond
COVID-19 as an effective approach to increase partici-
pation and improve the external validity of our research.
Video links
Control video: https://youtu.be/BzGHxV4-Yw0
Video decision aid for males: https://youtu.be/p_
Ey908EApE
Video decision aid for females: https://youtu.be/cDf_3
mlJRoU
Abbreviations
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